Details
Stereochemistry | ACHIRAL |
Molecular Formula | 2C10H10ClO3.Ca |
Molecular Weight | 467.353 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Ca++].CC(C)(OC1=CC=C(Cl)C=C1)C([O-])=O.CC(C)(OC2=CC=C(Cl)C=C2)C([O-])=O
InChI
InChIKey=IXCILCKRXAZYGP-UHFFFAOYSA-L
InChI=1S/2C10H11ClO3.Ca/c2*1-10(2,9(12)13)14-8-5-3-7(11)4-6-8;/h2*3-6H,1-2H3,(H,12,13);/q;;+2/p-2
Molecular Formula | Ca |
Molecular Weight | 40.078 |
Charge | 2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C10H10ClO3 |
Molecular Weight | 213.638 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Clofibrate is a fibric acid derivative used to lower cholesterol and triglyceride (fat-like substances) levels in the blood. This may help prevent medical problems caused by such substances clogging the blood vessels. However, this treatment was discontinued in 2002 due to adverse effects. Clofibrate is an agonist of the PPAR-α receptor in muscle, liver, and other tissues. This agonism ultimately leads to modification in gene expression resulting in increased beta-oxidation, decreased triglyceride secretion, increased HDL, and increased lipoprotein lipase activity. Clofibrate increased the activity of extrahepatic lipoprotein lipase (LL), thereby increasing lipoprotein triglyceride lipolysis, inhibited the synthesis, and increases the clearance of apolipoprotein B, a carrier molecule for VLDL. In addition, clofibrate was investigated as a novel therapy agent in multiple myeloma and it shown the promising results.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL239 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19817384 |
50.0 µM [EC50] | ||
Target ID: Q7RTX0 Gene ID: 83756.0 Gene Symbol: TAS1R3 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/19817384 |
28.0 µM [IC50] | ||
Target ID: CHEMBL239 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10922459 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ATROMID-S Approved UseUnknown Launch Date1967 |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
216 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7550835/ |
100 mg/kg single, oral dose: 100 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
CLOFIBRIC ACID plasma | Homo sapiens population: UNHEALTHY age: NEWBORN sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
30649 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7550835/ |
100 mg/kg single, oral dose: 100 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
CLOFIBRIC ACID plasma | Homo sapiens population: UNHEALTHY age: NEWBORN sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
103.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7550835/ |
100 mg/kg single, oral dose: 100 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
CLOFIBRIC ACID plasma | Homo sapiens population: UNHEALTHY age: NEWBORN sex: FEMALE / MALE food status: UNKNOWN |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/16316932/ Page: 6.0 |
moderate [Inhibition 100 uM] | |||
no | ||||
not significant | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/7685601/ |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/7685601/ |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/11033061/ |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Effects of clofibrate in primary biliary cirrhosis hypercholesterolemia and gallstones. | 1975 Oct |
|
[A 50-year history of new drugs in Japan: the developments and trends of antihyperlipidemic drugs]. | 2001 |
|
[Fibrate influence on lipids and insulin resistance in patients with metabolic syndrome]. | 2001 |
|
Use of isotopes and LC-MS-ESI-TOF for mechanistic studies of tienilic acid metabolic activation. | 2001 |
|
How well tolerated are lipid-lowering drugs? | 2001 |
|
[Necrotizing myopathies]. | 2001 |
|
Characterization of clofibrate-induced retrograde Golgi membrane movement to the endoplasmic reticulum: clofibrate distinguishes the Golgi from the trans Golgi network. | 2001 Aug |
|
Binding constant determination of drugs toward subdomain IIIA of human serum albumin by near-infrared dye-displacement capillary electrophoresis. | 2001 Aug |
|
PPARalpha-dependent induction of liver microsomal esterification of estradiol and testosterone by a prototypical peroxisome proliferator. | 2001 Aug |
|
Peroxisome proliferator-activated receptor alpha (PPAR alpha) agonist, WY-14,643, increased transcription of myosin light chain-2 in cardiomyocytes. | 2001 Dec |
|
The use of fibrates and of statins in preventing atherosclerosis in diabetes. | 2001 Dec |
|
Detection of DNA adducts using a quantitative long PCR technique and the fluorogenic 5' nuclease assay (TaqMan). | 2001 Dec 12 |
|
The transcription of the peroxisome proliferator-activated receptor alpha gene is regulated by protein kinase C. | 2001 Dec 15 |
|
Peroxisome proliferator-activated receptors (PPAR) and the mitochondrial aldehyde dehydrogenase (ALDH2) promoter in vitro and in vivo. | 2001 Jul |
|
Hormonal regulation of multiple promoters of the rat mitochondrial glycerol-3-phosphate dehydrogenase gene: identification of a complex hormone-response element in the ubiquitous promoter B. | 2001 Jul |
|
Localization of mRNAs encoding peroxisomal proteins in cell culture by non-radioactive in situ hybridization. Comparison of rat and human hepatoma cells and their responses to two divergent hypolipidemic drugs. | 2001 Jun |
|
Contribution of CYP1A2 in the hepatic metabolism of melatonin: studies with isolated microsomal preparations and liver slices. | 2001 Nov |
|
A systematic gene expression screen of Caenorhabditis elegans cytochrome P450 genes reveals CYP35 as strongly xenobiotic inducible. | 2001 Nov 15 |
|
Autoantibodies to lipids in bronchoalveolar lavage fluid of patients with acute respiratory distress syndrome. | 2001 Oct |
|
Mechanism of clofibrate hepatotoxicity: mitochondrial damage and oxidative stress in hepatocytes. | 2001 Sep 1 |
|
Comparison of various characteristics of women who do and do not attend for breast cancer screening. | 2002 |
|
Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro. | 2002 Apr |
|
Role of hypolipidemic drug clofibrate in altering iron regulatory proteins IRP1 and IRP2 activities and hepatic iron metabolism in rats fed a low-iron diet. | 2002 Apr 15 |
|
Effects of fatty acids on mitochondrial beta-oxidation enzyme gene expression in renal cell lines. | 2002 Aug |
|
Eighth World Congress of Intensive and Critical Care Medicine, 28 October-1 November 2001, Sydney, Australia: Harm minimization and effective risk management. | 2002 Feb |
|
Do lipid-lowering drugs cause erectile dysfunction? A systematic review. | 2002 Feb |
|
Characterization of catechol glucuronidation in rat liver. | 2002 Feb |
|
Synergistic effect of 4-hydroxynonenal and PPAR ligands in controlling human leukemic cell growth and differentiation. | 2002 Feb 1 |
|
In vitro induction of bilirubin conjugation in primary rat hepatocyte culture. | 2002 Feb 15 |
|
Peroxisome proliferator-activated receptor ligands as antiatherogenic agents: panacea or another Pandora's box? | 2002 Jan |
|
Topical peroxisome proliferator activated receptor-alpha activators reduce inflammation in irritant and allergic contact dermatitis models. | 2002 Jan |
|
CYP1A-mediated metabolism of the Janus kinase-3 inhibitor 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline: structural basis for inactivation by regioselective O-demethylation. | 2002 Jan |
|
Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB. | 2002 Jan 11 |
|
Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. | 2002 Jul |
|
PPARgamma ligands suppress proliferation of human urothelial basal cells in vitro. | 2002 Jun |
|
Prediction of compound signature using high density gene expression profiling. | 2002 Jun |
|
Gene expression analysis reveals chemical-specific profiles. | 2002 Jun |
|
Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2. | 2002 Jun 21 |
|
Influence of peroxisome proliferator-activated receptor alpha agonists on the intracellular turnover and secretion of apolipoprotein (Apo) B-100 and ApoB-48. | 2002 Jun 21 |
|
Presence and features of fatty acyl-CoA binding activity in rat hepatic peroxisomes. | 2002 Mar |
|
Potentiation of TNF-alpha-stimulated group IIA phospholipase A(2) expression by peroxisome proliferator-activated receptor alpha activators in rat mesangial cells. | 2002 Mar |
|
Effect of clofibrate administration on the esterification and deesterification of steroid hormones by liver and extrahepatic tissues in rats. | 2002 Mar 1 |
|
Myopathy and rhabdomyolysis with lipid-lowering drugs. | 2002 Mar 10 |
|
Clofibrate-induced relocation of phosphatidylcholine transfer protein to mitochondria in endothelial cells. | 2002 Mar 10 |
|
Getting a GRIP on liprins. | 2002 Mar 28 |
|
Blunted induction of hepatic CYP4A in TNF (p55-/-/p75-/-) double receptor knockout mice following clofibrate treatment. | 2002 May |
|
Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. | 2002 May |
|
Lipid-lowering drug use and cardiovascular events after myocardial infarction. | 2002 May |
|
Selective inhibition of cyclooxygenase-2 expression by 15-deoxy-Delta(12,14)(12,14)-prostaglandin J(2) in activated human astrocytes, but not in human brain macrophages. | 2002 May 1 |
|
Exposure simulation for pharmaceuticals in European surface waters with GREAT-ER. | 2002 May 10 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/cons/clofibrate.html
For oral dosage form (capsules): for high cholesterol: adults—1.5 to 2 grams a day. This is divided into two to four doses. Children—Dose must be determined by doctor.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27354598
The antitumor apoptotic effect of clofibrate at doses ranging from 0.1-600 μM was investigated on four human and one murine myeloma cell lines, as well as in two human lymphoma cell lines, using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-bromide assay. Clofibrate significantly reduced cell viability in all tested myeloma and lymphoma cell lines in a dose-dependent manner, while healthy cells were hardly affected.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:28:58 GMT 2023
by
admin
on
Fri Dec 15 16:28:58 GMT 2023
|
Record UNII |
TT85QFR500
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C98150
Created by
admin on Fri Dec 15 16:28:58 GMT 2023 , Edited by admin on Fri Dec 15 16:28:58 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
39087-48-4
Created by
admin on Fri Dec 15 16:28:58 GMT 2023 , Edited by admin on Fri Dec 15 16:28:58 GMT 2023
|
PRIMARY | |||
|
DTXSID60959904
Created by
admin on Fri Dec 15 16:28:58 GMT 2023 , Edited by admin on Fri Dec 15 16:28:58 GMT 2023
|
PRIMARY | |||
|
SUB06050MIG
Created by
admin on Fri Dec 15 16:28:58 GMT 2023 , Edited by admin on Fri Dec 15 16:28:58 GMT 2023
|
PRIMARY | |||
|
254-284-8
Created by
admin on Fri Dec 15 16:28:58 GMT 2023 , Edited by admin on Fri Dec 15 16:28:58 GMT 2023
|
PRIMARY | |||
|
C75993
Created by
admin on Fri Dec 15 16:28:58 GMT 2023 , Edited by admin on Fri Dec 15 16:28:58 GMT 2023
|
PRIMARY | |||
|
100000081593
Created by
admin on Fri Dec 15 16:28:58 GMT 2023 , Edited by admin on Fri Dec 15 16:28:58 GMT 2023
|
PRIMARY | |||
|
TT85QFR500
Created by
admin on Fri Dec 15 16:28:58 GMT 2023 , Edited by admin on Fri Dec 15 16:28:58 GMT 2023
|
PRIMARY | |||
|
CHEMBL683
Created by
admin on Fri Dec 15 16:28:58 GMT 2023 , Edited by admin on Fri Dec 15 16:28:58 GMT 2023
|
PRIMARY | |||
|
68659
Created by
admin on Fri Dec 15 16:28:58 GMT 2023 , Edited by admin on Fri Dec 15 16:28:58 GMT 2023
|
PRIMARY | |||
|
3848
Created by
admin on Fri Dec 15 16:28:58 GMT 2023 , Edited by admin on Fri Dec 15 16:28:58 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |